[go: up one dir, main page]

AR053208A1 - Forma cristalina de un compuesto de quinolinona carboxamida - Google Patents

Forma cristalina de un compuesto de quinolinona carboxamida

Info

Publication number
AR053208A1
AR053208A1 ARP060101375A ARP060101375A AR053208A1 AR 053208 A1 AR053208 A1 AR 053208A1 AR P060101375 A ARP060101375 A AR P060101375A AR P060101375 A ARP060101375 A AR P060101375A AR 053208 A1 AR053208 A1 AR 053208A1
Authority
AR
Argentina
Prior art keywords
quinolinona
carboxamida
compound
crystal form
salt forms
Prior art date
Application number
ARP060101375A
Other languages
English (en)
Inventor
Paul R Fatheree
S Derek Turner
Adam A Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR053208A1 publication Critical patent/AR053208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una sal clorhidrato cristalina de {(1S,3R,5R)-8-[( R )-2-hidroxi-3-(metansulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida de ácido 1-isopropil-2-oxo-1,2-dihidroquinolin-3-carboxílico o un solvato del mismo. Composiciones farmacéuticas que comprenden dichas formas salinas cristalinas, métodos para utilizar dichas formas salinas cristalinas para tratar enfermedades asociadas con la actividad del receptor 5 HT4, y procesos utiles para preparar dichas formas salinas cristalinas.
ARP060101375A 2005-04-06 2006-04-06 Forma cristalina de un compuesto de quinolinona carboxamida AR053208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
AR053208A1 true AR053208A1 (es) 2007-04-25

Family

ID=37074104

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101375A AR053208A1 (es) 2005-04-06 2006-04-06 Forma cristalina de un compuesto de quinolinona carboxamida
ARP170103029A AR110019A2 (es) 2005-04-06 2017-11-01 Forma cristalina de un compuesto de quinolinona-carboxamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170103029A AR110019A2 (es) 2005-04-06 2017-11-01 Forma cristalina de un compuesto de quinolinona-carboxamida

Country Status (29)

Country Link
US (4) US7728004B2 (es)
EP (1) EP1874766B1 (es)
JP (2) JP5230407B2 (es)
KR (1) KR101322873B1 (es)
CN (1) CN101151264B (es)
AR (2) AR053208A1 (es)
AT (1) ATE479682T1 (es)
AU (1) AU2006232129B2 (es)
BR (1) BRPI0610657A2 (es)
CA (1) CA2603654C (es)
CY (1) CY1111275T1 (es)
DE (1) DE602006016586D1 (es)
DK (1) DK1874766T3 (es)
EA (1) EA012115B1 (es)
ES (1) ES2350495T3 (es)
HR (1) HRP20100629T1 (es)
IL (1) IL186023A (es)
MA (1) MA29403B1 (es)
MX (1) MX2007012438A (es)
MY (1) MY151075A (es)
NO (1) NO339699B1 (es)
NZ (1) NZ561900A (es)
PE (1) PE20061310A1 (es)
PL (1) PL1874766T3 (es)
PT (1) PT1874766E (es)
SI (1) SI1874766T1 (es)
TW (1) TWI377206B (es)
WO (1) WO2006108127A2 (es)
ZA (1) ZA200708071B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
EP1807422B1 (en) * 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
KR101331768B1 (ko) 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
HRP20170241T2 (hr) 2007-12-07 2023-03-17 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
HRP20180018T1 (hr) 2009-04-13 2018-02-09 Theravance Biopharma R&D Ip, Llc Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
RU2718044C2 (ru) 2013-11-12 2020-03-30 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
PT3661518T (pt) * 2017-07-31 2024-11-04 Alfasigma Spa Métodos de tratamento dos sintomas da gastroparesia usando velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
IL319356A (en) 2022-09-20 2025-05-01 Alfasigma Spa Velostrag for use in the treatment of chronic pseudointestinal obstruction (CIPO)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
EP0670319A4 (en) 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
EP1807422B1 (en) 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
AU2006218603A1 (en) 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
EA200702161A1 (ru) 2008-04-28
AU2006232129B2 (en) 2012-07-12
US20160095849A1 (en) 2016-04-07
ZA200708071B (en) 2008-10-29
CY1111275T1 (el) 2015-08-05
DE602006016586D1 (de) 2010-10-14
CA2603654C (en) 2014-05-27
ATE479682T1 (de) 2010-09-15
MX2007012438A (es) 2007-12-05
US20140256769A1 (en) 2014-09-11
CN101151264A (zh) 2008-03-26
WO2006108127A3 (en) 2007-01-04
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
WO2006108127A2 (en) 2006-10-12
IL186023A0 (en) 2008-01-20
EA012115B1 (ru) 2009-08-28
AR110019A2 (es) 2019-02-13
TWI377206B (en) 2012-11-21
CN101151264B (zh) 2011-07-06
KR101322873B1 (ko) 2013-10-30
MY151075A (en) 2014-03-31
PE20061310A1 (es) 2007-01-23
EP1874766A2 (en) 2008-01-09
JP2008535848A (ja) 2008-09-04
US20100197728A1 (en) 2010-08-05
US20060229332A1 (en) 2006-10-12
CA2603654A1 (en) 2006-10-12
MA29403B1 (fr) 2008-04-01
ES2350495T3 (es) 2011-01-24
SI1874766T1 (sl) 2010-12-31
JP5230407B2 (ja) 2013-07-10
US9126994B2 (en) 2015-09-08
AU2006232129A1 (en) 2006-10-12
PT1874766E (pt) 2010-11-30
NO20075574L (no) 2007-11-02
JP2012153725A (ja) 2012-08-16
HK1110866A1 (en) 2008-07-25
US7728004B2 (en) 2010-06-01
NO339699B1 (no) 2017-01-23
HRP20100629T1 (hr) 2010-12-31
IL186023A (en) 2011-09-27
PL1874766T3 (pl) 2011-02-28
NZ561900A (en) 2010-12-24
TW200643020A (en) 2006-12-16
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
BRPI0610657A2 (pt) 2010-07-13
KR20070116988A (ko) 2007-12-11

Similar Documents

Publication Publication Date Title
AR053208A1 (es) Forma cristalina de un compuesto de quinolinona carboxamida
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
UY31265A (es) (2s,3 r)-n-( 2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CU20150020A7 (es) Composición farmacéutica recubierta que contiene regorafenib
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0917608B8 (pt) formulação de droga oral para a redução de potencial efeito abusivo, processo para a fabricação de uma formulação de droga e seu uso
AR062148A1 (es) Proceso quimico para la preparacion de intermediarios
HN2001000268A (es) Formas de sal de amida de acido 3 - (4-bromo - 2, 6 - difluorobenciloxi) - 5 - [3 - (4 - pirrolidin - 1 - ilbutil) ureido] isotiazol - 4 - carboxilico y metodo de produccion.
AR109224A2 (es) Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
MX2010006608A (es) Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
AR065519A1 (es) Sales de adicion de acido, hidratos y polimorfos de la etil - amida del acido 5- (2,4- dihidroxi -5- isopropil - fenil )-4-(4- morfolin-4-il-metil - fenil ) - isoxasol-3- carboxilico y formulaciones que comprenden estas formas
CO7071134A2 (es) Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea
MX2019009288A (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, metodos de fabricacion, y metodos de utilizacion.
AR062124A1 (es) Moduladores de la actividad del receptor de quimiocina formas cristalinas y procesos
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
BRPI0606199A2 (pt) hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento
AR055741A1 (es) Sales de adicion de derivado de quinuclidina y composicion farmaceutica
GT200600421A (es) Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
BRPI0913736A2 (pt) Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central
AR065530A1 (es) Sal hidrocloruro de ( 1r; 2r;3s;5s)-2-metoximetil-3-(3;4-diclorofenil)-8-azabiciclo(3.2.1)octano, metodo para fabricar una forma farmaceutica de la misma, dosis liquida que la comprende y forma farmaceutica que comprende un sustrato de vehiculo y dicha sal
AR062561A1 (es) Composiciones kits y metodos de un programa de titulacion para compuestos de bifeprunox
TH81785B (th) รูปผลึกของสารประกอบควิโนลิโนน-คาร์บอกซามีด
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas

Legal Events

Date Code Title Description
FC Refusal